Selpercatinib as the Guardian of the Central Nervous System for Patients With RET Fusion-Positive NSCLC? - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37087118/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions/Relevance: With this report by Murciano-Goroff et al., selpercatinib has likely joined osimertinib and lorlatinib as agents with activity in the CNS for their respective mutant NSCLC subtypes. We look forward to identifying drugs to join the list of CNS active agents for ROS1+ and HER2 exon20...
Landscape of gene mutation in Chinese thyroid cancer patients: Construction and validation of lymph node metastasis prediction model based on clinical features and gene mutation marker - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37081757/
We provide a novel nomogram to predict the LNM for TC patients, including the features of patient's age, gender, tumor diameter, and RET alteration. Further studies from multiple medical centers...
Conclusion: We provide a novel nomogram to predict the LNM for TC patients, including the features of patient's age, gender, tumor diameter, and RET alteration. Further studies from multiple medical centers are essential to validate the nomogram.
Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based Inhibitors
Abstract. Selpercatinib (LOXO292) and pralsetinib (BLU667) are RET protein tyrosine kinase inhibitors (TKIs) recently approved for treating RET-altered cancers. However, RET mutations that confer selpercatinib/pralsetinib resistance have been identified, necessitating...
Conclusions/Relevance: This study clarifies the sensitivities of different RET solvent-front mutants to selpercatinib and pralsetinib, and identifies novel alkylnyl nicotinamide-based RET TKIs for inhibiting selpercatinib/pralsetinib-resistant G810 mutants.
Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical implications
Abstract. Biomarker-driven cancer therapy has revolutionized precision oncology. With a better understanding of tumor biology, tissue-agnostic targets have been characterized and explored which ultimately led to therapeutics with pan-cancer efficacy....
Conclusions/Relevance: In this article, we describe the distribution of those tissue-agnostic targets among different cancer types. In addition, we summarize the current prospect on the biology of these alterations and evidence on approved drugs including pembrolizumab, dostarilmab, larotrectinib, entrectinib, selpercatinib, and...
Highly sensitive droplet digital PCR for detection of RET fusion in papillary thyroid cancer - BMC Cancer
Source : https://bmccancer.biomedcentral.com/articles/10.1186/s12885-023-10852-z
Background Thyroid cancer is the most frequent malignancy of the endocrine system, of which papillary thyroid cancer (PTC) is the predominant form with a rapid increasing incidence worldwide. Rearranged during...
Conclusion: The accurate and sensitive ddPCR method reported here is powerful to detection CCDC6::RET fusion in PTC samples, application of this method would benefit more RET fusion-positive patients in the clinic.